Inside the Lab Where They Investigate Your Recurrent Pregnancy Loss
Recurrent pregnancy loss (RPL) is the loss of two or more pregnancies, and its investigation is a stepwise search for identifiable causes—not a single test that can explain every miscarriage. In the laboratory, clinicians may examine pregnancy tissue for chromosome changes, measure selected hormones, and test for antiphospholipid antibodies; findings are interpreted alongside medical history and imaging. The American Society for Reproductive Medicine estimates that RPL affects about 1% of people, while many early losses result from random chromosome abnormalities. Understanding what each test can—and cannot—show can help patients prepare for evaluation and avoid unsupported tests or treatments.
What recurrent pregnancy loss investigation means
The American Society for Reproductive Medicine (ASRM) defines recurrent pregnancy loss as two or more failed clinical pregnancies, with clinical pregnancy generally documented by ultrasound or examination of pregnancy tissue. The European Society of Human Reproduction and Embryology (ESHRE) likewise uses a threshold of two or more pregnancy losses, though definitions and eligibility for testing can differ among professional guidelines and health systems.
RPL is a clinical condition, not a diagnosis that automatically identifies one cause. A workup typically combines the patient’s pregnancy and medical history with selected blood tests, uterine assessment, and, in some cases, genetic analysis of pregnancy tissue or the parents. The goal is to identify causes with meaningful evidence and management options, while recognizing that a cause remains unexplained for many patients.
Why early losses and chromosome findings matter
Chromosomal abnormalities are a frequent explanation for individual early miscarriages. The American College of Obstetricians and Gynecologists (ACOG) notes that about half of early pregnancy losses are due to fetal chromosomal abnormalities, often arising by chance rather than being inherited. The likelihood of some chromosome errors increases with maternal age, but a prior loss does not establish that the next pregnancy will have the same cause.
A tissue result can sometimes explain a particular loss, but it does not by itself rule out other factors or predict every future pregnancy. The laboratory’s role is therefore both analytical and limited: it reports what the submitted sample supports, while clinicians interpret the result in context.
How pregnancy tissue and genetic testing are investigated
Products-of-conception testing examines tissue from a miscarriage for genetic abnormalities. Depending on the laboratory, methods may include chromosomal microarray or other chromosome analysis. These tests can identify certain gains or losses of chromosome material, but they do not detect every genetic condition and may be affected by sample quality or contamination with the pregnant patient’s cells.
Tissue testing: what the result can tell you
When tissue testing identifies an abnormal chromosome number or copy-number change, it may provide a plausible explanation for that pregnancy loss. A result reported as normal does not prove that the loss had no genetic basis: some changes are outside the test’s scope, and technical limitations can leave a result inconclusive. The clinician should explain the method used, whether the sample was adequate, and what the finding means for future pregnancies.
Testing is not available or appropriate in every situation. ASRM guidance describes genetic testing of miscarriage tissue as one possible part of evaluation, while emphasizing that decisions should reflect the clinical circumstances and patient preferences.
Parental chromosome testing
A parental karyotype examines chromosomes in a blood sample to look for structural rearrangements, such as a balanced translocation. A person with a balanced rearrangement may be healthy, yet some eggs or sperm can carry an unbalanced chromosome arrangement, increasing the possibility of miscarriage or an affected pregnancy. Such findings are uncommon, so guidelines differ on whether to test both partners routinely or use results from pregnancy tissue and family history to guide testing.
If a rearrangement is found, genetic counseling can explain reproductive options and the implications for relatives. A result does not mean that a healthy pregnancy is impossible, and decisions about prenatal testing or assisted reproduction should be individualized.
Blood tests for immune and endocrine causes
Blood testing in an RPL evaluation is targeted rather than an unlimited search for every possible abnormality. The clearest evidence-based blood-test category is testing for antiphospholipid syndrome (APS), an acquired autoimmune clotting disorder associated with pregnancy complications. Other tests may be appropriate when a patient’s history or symptoms suggest a thyroid, metabolic, or other medical condition.
Antiphospholipid antibody testing
APS testing commonly measures lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies. A single positive result is not enough to establish APS: laboratory abnormalities generally must be confirmed on repeat testing at least 12 weeks later and interpreted with the patient’s clinical history. Temporary antibody elevations can occur, so timing and confirmation matter.
ESHRE and other professional guidance support APS screening in recurrent pregnancy loss because confirmed APS can change care. For eligible patients, specialist-directed treatment may include low-dose aspirin and heparin. These medicines are not appropriate for everyone with a miscarriage history, and they should not be started without a clinician’s assessment.
Thyroid and other hormone testing
Thyroid-stimulating hormone testing can identify thyroid dysfunction, which is relevant to general health and pregnancy care. Additional thyroid antibody testing or treatment depends on clinical context and the guideline being followed; a positive antibody result alone does not necessarily establish the cause of losses or prove that treatment will prevent another one.
Testing for diabetes or other endocrine conditions may be considered when medical history or symptoms make it appropriate. By contrast, broad panels for inherited thrombophilia, natural-killer-cell activity, or many reproductive immune markers are not routinely recommended for every patient with RPL because evidence that testing or treating these findings improves outcomes is limited.
Uterine assessment and tests that need careful interpretation
A uterine assessment looks for structural features that may affect implantation or pregnancy development. Imaging is often as important as laboratory testing: a blood result cannot reveal whether the uterine cavity has a septum, fibroid, adhesion, or other anatomical finding.
Ultrasound and cavity imaging
Transvaginal ultrasound is commonly used to examine the uterus and ovaries. Depending on the initial findings, clinicians may recommend saline-infusion sonography, three-dimensional ultrasound, hysteroscopy, or other imaging to assess the uterine cavity more closely. The appropriate method depends on the suspected abnormality, prior procedures, and local practice.
Finding an anatomical difference does not automatically mean it caused the losses or that surgery will improve the chance of a live birth. The type and severity of the finding, the patient’s history, and the evidence for intervention should all be discussed before treatment.
Why some popular tests are not routine
Patients may encounter recommendations for extensive immune panels, infection screens, or clotting tests. Professional guidance cautions against tests that lack a clear link to improved outcomes, especially when they can generate uncertain or incidental results. A test is most useful when it answers a specific clinical question and when a reliable action follows from the result.
A useful question for the care team is: “If this result is positive or negative, how would it change my care?” If there is no evidence-based answer, the value of the test may be limited.
What happens in the lab—and how results reach patients
The phrase “inside the lab” covers different workflows. A tissue sample may be checked for identity and suitability, prepared for genetic analysis, and reviewed by laboratory specialists; a blood sample may be processed for antibody or hormone testing. Procedures vary by test and laboratory, so there is no single RPL laboratory protocol.
Sample handling, quality, and limitations
For pregnancy tissue, sample selection and handling can affect whether testing succeeds. Maternal-cell contamination is one reason a result may be difficult to interpret. For antibody testing, the exact assay, cutoff values, and repeat-testing interval matter. Clinicians should review the report’s technical notes rather than interpreting a result from a number alone.
From a result to a care plan
A laboratory report is one part of the investigation, not the final explanation. A clinician considers the result alongside the number and timing of losses, age, medical conditions, pregnancy tissue findings, and uterine imaging. When the evaluation identifies a treatable condition, management can be tailored; when it does not, supportive care and a plan for early follow-up in a future pregnancy remain important.
For many patients, no definitive cause is found despite evaluation. This is not evidence that the losses were imagined or caused by something the patient did. ACOG notes that many people who have experienced pregnancy loss go on to have successful pregnancies, although individual prospects depend on age and medical circumstances.
Conclusion: making the investigation useful and humane
Recurrent pregnancy loss investigation brings together pregnancy history, selected genetic and blood tests, and uterine assessment. Pregnancy-tissue analysis may clarify chromosome findings; parental testing can identify uncommon rearrangements; APS testing can uncover a condition with specific management; and thyroid or other evaluation is guided by clinical context. No single test explains every loss, and some commonly marketed panels have limited evidence.
If you are seeking evaluation, ask which guideline the clinic follows, what each test can detect, how an abnormal result would change care, and whether repeat testing or genetic counseling is needed. Consider care from an obstetrician-gynecologist or reproductive specialist experienced in RPL, and seek emotional support as well as medical follow-up. The investigation should provide clear information without promising certainty where the science cannot.
Sources: American Society for Reproductive Medicine, “Evaluation and treatment of recurrent pregnancy loss: a committee opinion,” 2012, https://www.asrm.org/practice-guidance/practice-committee-documents/evaluation-and-treatment-of-recurrent-pregnancy-loss-a-committee-opinion-2012/; European Society of Human Reproduction and Embryology, “ESHRE Guideline: Recurrent Pregnancy Loss,” 2022, https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss; American College of Obstetricians and Gynecologists, “Repeated Miscarriages,” https://www.acog.org/womens-health/faqs/repeated-miscarriages; American College of Obstetricians and Gynecologists, “Early Pregnancy Loss,” https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/11/early-pregnancy-loss.